An analyst from Redburn Partners has set a $127 price target for Abbott Laboratories, indicating a 31.3% upside from its recent price of around $96.71. Despite a recent decline in Abbott's stock, the company expects strong quarterly earnings of $1.43 per share and revenue growth to $12.91 billion. Abbott is also expanding its colorectal cancer screening portfolio with a new FDA-approved blood test, SimpleScreen CRC, targeting millions of Americans due for screening. The upcoming earnings report on October 21 will be key for investors to assess the company's performance against this optimistic outlook.
Ahead of Abbott Laboratories' upcoming earnings report, its stock is trading at USD 97.51 on Pluang as of Oct 02, 2026 20:15 WIB, showing a modest 0.83% gain for the day. The stock's market cap stands at $167.31 billion, with a dividend yield of 2.55%. Despite the positive analyst outlook, Pluang data shows that 84% of order activity is selling, indicating cautious investor sentiment.
Abbott Laboratories announced plans to spin off its Nutrition division to concentrate on higher-growth areas like diagnostics, medical devices, and pharmaceuticals. The company reported a 14.5% increase in Q3 revenue to $13.01 billion, driven mainly ...
Abbott Laboratories reported Q3 2026 results with adjusted earnings per share of $1.42, matching estimates, and revenue of $13.01 billion, slightly above expectations. Despite 14.5% sales growth, the company lowered its 2026 sales growth forecast due...
Abbott posted a 14.5% increase in reported sales and 7.0% comparable sales growth for Q3 2026, with GAAP diluted EPS of $0.53 and adjusted EPS of $1.42. The company expanded its portfolio with FDA approvals for innovative products like the Libre Duo ...
Abbott announced plans to separate its Nutrition business into a standalone, publicly traded company by the end of 2027. The new Nutrition company will focus on the growing healthy nutrition market with $8.5 billion in annual sales and iconic brands ...
